Metabolic heterogeneity and niche rewiring in bone marrow plasma cells from patients with MGUS, solitary bone plasmacytoma and multiple myeloma.
Multiple myeloma creates unique metabolic pockets visible only on tumor tissue, not blood—opening a path to predict progression and find new drug targets.
Using high-resolution mass spectrometry imaging on archived bone marrow biopsies from Mayo Clinic, this study maps spatial metabolic heterogeneity across the MGUS-to-MM spectrum, revealing that SBP with minimal marrow involvement already harbors MM-like metabolic niches — a finding invisible to conventional plasma metabolomics. The tryptophan-kynurenine flux rewiring in MM niches provides both a mechanistic target and a potential metabolite-based spatial risk stratification tool.
What the study was
- Study design
- Cross-sectional translational study — high-resolution MALDI-FT-ICR mass spectrometry imaging (MSI) on archived FFPE bone marrow biopsies + matched metabolomics (Mayo Clinic / Helmholtz Munich)
- Population
- Patients with MGUS-like bone marrows (including MGUS and SBP with minimal marrow involvement) and multiple myeloma
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Blood Cancer Journal
Why it surfaced
Highly novel spatial metabolomics methodology applied to a clinically important question (MGUS→MM progression) at a top center (Mayo Clinic). The finding that SBPmm already shows MM-like spatial metabolic features has risk stratification implications. Preliminary scale; needs validation in larger cohorts.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.